The costs of treatment of early and chronic pseudomonas aeruginosa infection in cystic fibrosis patients

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 188-192

  Braccini, G ^a   Festini, F ^a   Bom, V ^b   Neri, A S ^b   Galici, V ^a   Campana, S ^b   Zavataro, L ^b   Trevisan, F ^a   Braggion, C ^b   Taccetti, G ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antibiotic treatment; Cost; Cystic fibrosis; Early eradication treatment; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; MEROPENEM; TIMENTIN; TOBRAMYCIN;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC DISEASE; COST OF ILLNESS; CYSTIC FIBROSIS; DRUG COST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL PATIENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTPATIENT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 67249126729     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.188     Document Type: Article

References (20)

1. Baumann U, Stocklossa C, Greiner W, Graf von der Schu-lenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003; 2: 84-90.
2. Schrey6gg J, Hollmeyer H, Bluemel M, Staab D, Busse R. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006; 24: 999-1009.
3. Krauth C, Jalilvand N, Welt T, Busse R. Cystic fibrosis; cost of illness and consideration for the economic evaluation of potential therapies. Pharmacoeconomics 2003; 21:1001-24.
4. Johnson JA, Connonly MA, Jacobs P, Montgomery M, Brown NE, Zuberbuler P. Cost of care for individuate with cystic fibrosis: a regression approach to determining the impact of re-combinant human DNase. Pharmacotherapy 1999; 19: 1159-66.
5. Ratjen F, Doring G. Cystic fibrosis. Lancet. 2003; 361:681-9.
6. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749-67.
7. Pseudomonas aeruginosa infection in people with cystic fibrosis. Suggestion for prevention and infection control. Report of the UK Cystic Fibrosis Trust Infection Control Group. Cystic Fibrosis Trust, Bromley 2004 8 Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2006 Jan 25;(l):CD004197.
8. Ratien F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006;12: 428-32.
9. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mo-gayzel PJ Jr, Willey-Courand DB, et al. and Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176: 957-69.
10. lies R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibres 2003; 2: 120-8.
11. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-61.
12. Prontuario farmaceutico nazionale 2006 [Italian Directory of Medicine] website. (Accessed March 14, 2008 at http://www.asl.fr.it/farmaci/NuovoPrFarm. Ddf. )
13. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5.
14. Kerem E, Conway S, Elborn S, Heijerman H for the Con sensus Committee. Standards of care for patients with cystic fibrosis: A European consensus. J Cyst Fibros 2005; 4: 7-26.
15. Huot L, Durieu I, Bourdy S, Ganne C, Bellon G, Colin C, Touzet S. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J Cyst Fibros 2008; in press.
16. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
17. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2003;(3):CD001021.
18. Thornton J, Elliott RA, Tully MP, Dodd M. Webb AK. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros 2005; 4: 239-247
19. Doring G, Fteiby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3: 67-91.
20. van den Akker-van Marie ME, Dankert HM, Verkerk PH. Dankert-Roelse JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006; 118:896-905